[go: up one dir, main page]

WO2005014035A3 - Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest - Google Patents

Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest Download PDF

Info

Publication number
WO2005014035A3
WO2005014035A3 PCT/DK2004/000530 DK2004000530W WO2005014035A3 WO 2005014035 A3 WO2005014035 A3 WO 2005014035A3 DK 2004000530 W DK2004000530 W DK 2004000530W WO 2005014035 A3 WO2005014035 A3 WO 2005014035A3
Authority
WO
WIPO (PCT)
Prior art keywords
protractor
molecules
proteins
chemical conjugation
selective chemical
Prior art date
Application number
PCT/DK2004/000530
Other languages
French (fr)
Other versions
WO2005014035A2 (en
Inventor
Carsten Behrens
Patrick William Garibay
Magali Zundel
Niels Kristian Klausen
Soeren E Bjoern
Original Assignee
Novo Nordisk Healthcare Ag
Carsten Behrens
Patrick William Garibay
Magali Zundel
Niels Kristian Klausen
Soeren E Bjoern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag, Carsten Behrens, Patrick William Garibay, Magali Zundel, Niels Kristian Klausen, Soeren E Bjoern filed Critical Novo Nordisk Healthcare Ag
Priority to EP04739027A priority Critical patent/EP1653996A2/en
Priority to JP2006522893A priority patent/JP2007501811A/en
Publication of WO2005014035A2 publication Critical patent/WO2005014035A2/en
Publication of WO2005014035A3 publication Critical patent/WO2005014035A3/en
Priority to US11/339,752 priority patent/US20060198819A1/en
Priority to US12/060,383 priority patent/US20100028939A1/en
Priority to US14/264,678 priority patent/US20140274903A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes.
PCT/DK2004/000530 2003-08-08 2004-08-09 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest WO2005014035A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04739027A EP1653996A2 (en) 2003-08-08 2004-08-09 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
JP2006522893A JP2007501811A (en) 2003-08-08 2004-08-09 Use of galactose oxidase for selective chemical conjugation of a retarder molecule to a protein of therapeutic interest.
US11/339,752 US20060198819A1 (en) 2003-08-08 2006-01-25 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
US12/060,383 US20100028939A1 (en) 2003-08-08 2008-04-01 Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest
US14/264,678 US20140274903A1 (en) 2003-08-08 2014-04-29 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200301145 2003-08-08
DKPA200301145 2003-08-08
US49444703P 2003-08-12 2003-08-12
US60/494,447 2003-08-12
DKPA200301646 2003-11-05
DKPA200301646 2003-11-05
US51921203P 2003-11-12 2003-11-12
US60/519,212 2003-11-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/339,752 Continuation US20060198819A1 (en) 2003-08-08 2006-01-25 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest

Publications (2)

Publication Number Publication Date
WO2005014035A2 WO2005014035A2 (en) 2005-02-17
WO2005014035A3 true WO2005014035A3 (en) 2005-07-28

Family

ID=34139681

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/DK2004/000530 WO2005014035A2 (en) 2003-08-08 2004-08-09 Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
PCT/DK2004/000531 WO2005014049A2 (en) 2003-08-08 2004-08-09 Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000531 WO2005014049A2 (en) 2003-08-08 2004-08-09 Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides

Country Status (3)

Country Link
EP (2) EP1654004A2 (en)
JP (3) JP2007501811A (en)
WO (2) WO2005014035A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7541328B2 (en) 2002-03-06 2009-06-02 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
JP4674702B2 (en) 2003-04-09 2011-04-20 バイオジェネリクス エージー Glycopegylation method and protein / peptide produced by the method
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP2263684A1 (en) * 2003-10-10 2010-12-22 Novo Nordisk A/S IL-21 derivatives
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2339953T5 (en) 2004-05-04 2020-05-06 Novo Nordisk Healthcare Ag O-linked factor VII glycoforms and method of manufacture
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
ES2566670T3 (en) 2004-10-29 2016-04-14 Ratiopharm Gmbh Remodeling and glucopegilation of fibroblast growth factor (FGF)
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
US20090036353A1 (en) * 2005-01-27 2009-02-05 Novo Nordisk A/S Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers
CA2601745A1 (en) * 2005-02-16 2006-08-24 Novo Nordisk A/S Insulinotropic agents conjugated with structurally well defined branched polymers
WO2006094826A2 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Method for coupling enzymatically activated glycoconjugates to a hydroxyalkyl starch
KR20070110902A (en) * 2005-03-11 2007-11-20 프레제니우스 카비 도이치란트 게엠베하 Production of Bioactive Glycoproteins from Inert Starting Materials
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
EP1863521B1 (en) 2005-03-18 2014-05-07 Novo Nordisk A/S Extended glp-1 compounds
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1896082B1 (en) 2005-06-16 2012-12-26 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
DE602005017628D1 (en) 2005-09-22 2009-12-24 Biocompatibles Uk Ltd Fusion polypeptides of glp-1 (glucagon-like peptide-1) with increased peptidase resistance
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CU23556A1 (en) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech POLYMER STRUCTURE SIMILAR TO DENDRÍMERO FOR THE OBTAINING OF CONJUGATES OF PHARMACEUTICAL INTEREST
US8293869B2 (en) 2005-12-16 2012-10-23 Nektar Therapeutics Polymer conjugates of GLP-1
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
US8268948B2 (en) 2006-07-21 2012-09-18 Nektar Therapeutics Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
ES2516694T3 (en) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glycosylation of peptides through glycosylation sequences with O-binding
WO2008025856A2 (en) 2006-09-01 2008-03-06 Novo Nordisk Health Care Ag Modified glycoproteins
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
CN103804489A (en) 2006-12-15 2014-05-21 巴克斯特国际公司 Factor viia-(poly)sialic acid conjugate having prolonged in vivo half-life
CN101588819B (en) 2006-12-27 2012-11-21 尼克塔治疗公司 Factor ix moiety-polymer conjugates having a releaseable linkage
CN101678119B (en) 2006-12-27 2014-02-12 尼克塔治疗公司 von Willebrand factor- and factor VIII-polymer conjugates with releasable linkage
PT2457919T (en) 2007-01-18 2019-09-20 Genzyme Corp Oligosaccharides comprising an aminooxy group and conjugates thereof
JP2010523582A (en) 2007-04-03 2010-07-15 バイオジェネリクス アクチェンゲゼルシャフト Treatment method using glycoPEGylated G-CSF
PL2157967T3 (en) * 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
ES2551123T3 (en) 2007-06-12 2015-11-16 Ratiopharm Gmbh Improved process for the production of nucleotide sugars
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
BRPI0917000A2 (en) 2008-08-06 2016-02-16 Novo Nordisk Healthcare Ag protein conjugates with prolonged in vivo efficacy
TR201909909T4 (en) 2008-12-16 2019-07-22 Genzyme Corp Oligosaccharide-protein conjugates.
KR20110122100A (en) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Stable growth hormone compounds
JP5418360B2 (en) 2009-03-27 2014-02-19 日油株式会社 Method for producing polyoxyalkylene derivative
CA2769244A1 (en) 2009-07-27 2011-02-03 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
PL2459224T3 (en) 2009-07-27 2017-08-31 Baxalta GmbH Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
NZ598056A (en) 2009-07-27 2014-01-31 Baxter Int Blood coagulation protein conjugates
US8841249B2 (en) 2009-08-06 2014-09-23 Novo Nordisk A/S Growth hormones with prolonged in-vivo efficacy
EP2507267B1 (en) 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
TWI484974B (en) 2009-12-16 2015-05-21 Novo Nordisk As Double-acylated glp-1 derivatives
CA2787895A1 (en) 2010-01-22 2011-07-28 Novo Nordisk Health Care Ag Stable growth hormone compounds
BR112012018116B1 (en) 2010-01-22 2022-06-21 Novo Nordisk Health Care Ag Growth hormone conjugates with prolonged in vivo efficacy
KR20190104442A (en) 2010-07-09 2019-09-09 바이오버라티브 테라퓨틱스 인크. Factor ix polypeptides and methods of use thereof
MX345501B (en) 2010-12-16 2017-02-02 Novo Nordisk As Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid.
BR112013015898A2 (en) 2010-12-22 2018-06-26 Baxter International Inc. water soluble fatty acid derivative, and methods for preparing a fatty acid derivative and a conjugated therapeutic protein.
US8901341B2 (en) * 2011-02-11 2014-12-02 Bezwada Biomedical, Llc Amino acid derivatives and absorbable polymers therefrom
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
WO2012170938A1 (en) 2011-06-08 2012-12-13 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life
US9790305B2 (en) * 2011-09-09 2017-10-17 Franklin And Marshall College Site specifically incorporated initiator for growth of polymers from proteins
RS57727B1 (en) 2012-03-22 2018-12-31 Novo Nordisk As Compositions of glp-1 peptides and preparation thereof
TR201903918T4 (en) 2012-03-22 2019-04-22 Novo Nordisk As Compositions containing a dispersing agent and their preparation.
JP6517690B2 (en) 2012-06-20 2019-05-22 ノヴォ ノルディスク アー／エス Tablet formulation containing peptide and delivery agent
JP2015533152A (en) 2012-10-15 2015-11-19 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Factor VII conjugate
WO2014166836A1 (en) 2013-04-05 2014-10-16 Novo Nordisk A/S Growth hormone compound formulation
ES2688462T3 (en) 2013-05-02 2018-11-02 Novo Nordisk A/S Oral dosage of GLP-1 compounds
JP2016537321A (en) 2013-10-15 2016-12-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Coagulation factor VII polypeptide
US10995148B2 (en) * 2014-03-19 2021-05-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
JP6894239B2 (en) * 2014-05-27 2021-06-30 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Compositions and methods for universal glycoforms for enhanced antibody efficacy
CN107533069A (en) * 2015-03-06 2018-01-02 泰摩拉分析运营有限责任公司 Array for the chemically functionalization of analyzing proteins modification
CN106478806B (en) * 2016-10-24 2019-08-30 合肥国肽生物科技有限公司 A kind of solid phase synthesis process of Suo Malu peptide
CN118873634A (en) 2018-02-02 2024-11-01 诺和诺德股份有限公司 Solid composition comprising a GLP-1 agonist, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
WO1996036357A1 (en) * 1995-05-15 1996-11-21 Bona Constantin A Carbohydrate-mediated coupling of peptides to immunoglobulins
US5714166A (en) * 1986-08-18 1998-02-03 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
US20010043929A1 (en) * 1993-03-23 2001-11-22 Alza Corporation Enhanced circulation effector composition and method
US20030096338A1 (en) * 2000-02-11 2003-05-22 Pedersen Anders Hjelholt Factor VII or VIIa-like molecules

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
AU720860B2 (en) * 1996-10-08 2000-06-15 Macquarie Research Limited Glycan derivatives
JP2927291B2 (en) * 1997-09-01 1999-07-28 東洋インキ製造株式会社 Dendrimer containing vinyl group
US6485718B1 (en) * 1999-04-13 2002-11-26 Pharmacia Corporation Site specific ligation of proteins to synthetic particles
AU5522600A (en) * 1999-06-29 2001-01-22 Dako A/S Detection using dendrimers bearing labels and probes
RU2003104024A (en) * 2000-07-12 2004-06-27 Грифон Терапьютикс, Инк. (Us) POLYMER-MODIFIED BIOACTIVE SYNTHETIC CHEMOKINS AND METHODS OF THEIR PREPARATION AND APPLICATION
AU2002240312A1 (en) * 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US7026440B2 (en) * 2001-11-07 2006-04-11 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714166A (en) * 1986-08-18 1998-02-03 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US20010043929A1 (en) * 1993-03-23 2001-11-22 Alza Corporation Enhanced circulation effector composition and method
WO1994028024A1 (en) * 1993-06-01 1994-12-08 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
WO1996036357A1 (en) * 1995-05-15 1996-11-21 Bona Constantin A Carbohydrate-mediated coupling of peptides to immunoglobulins
US20030096338A1 (en) * 2000-02-11 2003-05-22 Pedersen Anders Hjelholt Factor VII or VIIa-like molecules

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EDANO TOSHIYUKI ET AL: "Importance of sialic acid in recombinant thrombomodulin in terms of pharmacokinetics and separation of desialyzed glycoprotein", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 21, no. 4, April 1998 (1998-04-01), pages 382 - 385, XP009034122, ISSN: 0918-6158 *
FU QINGLAN ET AL: "Carbohydrate-directed conjugation of cobra venom factor to antibody by selective derivatization of the terminal galactose residues", BIOCONJUGATE CHEMISTRY, vol. 12, no. 2, March 2001 (2001-03-01), pages 271 - 279, XP002290190, ISSN: 1043-1802 *
MADNICK H M ET AL: "Effect of modification of galactose residues on the biological properties of asialo human choriogonadotropin.", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS. DEC 1981, vol. 212, no. 2, December 1981 (1981-12-01), pages 432 - 442, XP009034110, ISSN: 0003-9861 *
RICE K G ET AL: "MODIFICATION OF TRIANTENNARY GLYCOPEPTIDE INTO PROBES FOR THE ASIALOGLYCOPROTEIN RECEPTOR OF HEPATOCYTES", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 30, 1990, pages 18423 - 18428, XP002290191, ISSN: 0021-9258 *
See also references of EP1653996A2 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541328B2 (en) 2002-03-06 2009-06-02 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein

Also Published As

Publication number Publication date
WO2005014049A2 (en) 2005-02-17
WO2005014035A2 (en) 2005-02-17
EP1653996A2 (en) 2006-05-10
JP2011157365A (en) 2011-08-18
WO2005014049A3 (en) 2005-09-01
JP2007501811A (en) 2007-02-01
JP2007501812A (en) 2007-02-01
EP1654004A2 (en) 2006-05-10

Similar Documents

Publication Publication Date Title
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO2002008285A3 (en) Il-17 molecules and uses thereof
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2004064595A3 (en) Multivalent constructs for therapeutic and diagnostic applications
WO2002002624A3 (en) B7-like molecules and uses thereof
WO2002024891A3 (en) B7-like molecules and uses thereof
DE60138715D1 (en) TNF-RECEPTOR-SIMILAR MOLECULES AND THEIR APPLICATIONS
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
WO2001068859A3 (en) Il-17 receptor like molecules and uses thereof
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
WO2001032935A3 (en) Molecular microarrays and methods for production and use thereof
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2004076614A3 (en) Human nucleic acid sequences obtained from prostatic carcinomas
WO2002010388A3 (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF
WO2003102185A3 (en) Methods and compositions for treating neoplasia relating to hnrnp a1 and a2 nucleic acid molecules
WO2003055980A3 (en) Il-17 like molecules and uses thereof
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
WO2004085614A3 (en) Nucleic acid molecules that are differentially regulated in a bipolar disorder and uses thereof
WO2005089294A3 (en) Synthesis of indenoisoquinoliniums and methods of use
WO2002097046A3 (en) B7 related protein-2 molecules and uses thereof
WO2005023979A3 (en) Isolated s. mansoni nucleic acid molecules and uses thereof
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004739027

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11339752

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006522893

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004739027

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11339752

Country of ref document: US